Cargando…

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma

Clinicians routinely prescribe adjuvant chemotherapy (ACT) for resected non-small cell lung cancer patients. However, ACT only improves five-year disease-free survival in stage I-III non-small cell lung cancer by 5-15%, with most patients deriving no benefit. Herein, deregulation of the E2F pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lu, Kurtyka, Courtney A, Welsh, Eric A, Rivera, Jason I, Engel, Brienne E, Muñoz-Antonia, Teresita, Yoder, Sean J, Eschrich, Steven A, Creelan, Ben C, Chiappori, Alberto A, Gray, Jhanelle E, Ramirez, Jose Luis, Rosell, Rafael, Schabath, Matthew B, Haura, Eric B, Chen, Dung-Tsa, Cress, Douglas W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347689/ https://www.ncbi.nlm.nih.gov/pubmed/27756884 http://dx.doi.org/10.18632/oncotarget.12672

Ejemplares similares

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
por: Schabath, Matthew B., et al.
Publicado: (2015)

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
por: Chen, Dung-Tsa, et al.
Publicado: (2021)

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018)

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2019)

Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2021)

A Bayesian pick-the-winner design in a randomized phase II clinical trial
por: Chen, Dung-Tsa, et al.
Publicado: (2017)

Strategies for power calculations in predictive biomarker studies in survival data
por: Chen, Dung-Tsa, et al.
Publicado: (2016)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019)

E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines
por: Kurtyka, Courtney A., et al.
Publicado: (2014)

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Chen, Dung-Tsa, et al.
Publicado: (2023)

A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses
por: Boyle, Theresa A., et al.
Publicado: (2019)

Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer
por: Tanvetyanon, Tawee, et al.
Publicado: (2023)

Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes
por: Hudson, Janella, et al.
Publicado: (2016)

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
por: Gray, Jhanelle E., et al.
Publicado: (2018)

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer
por: Kim, Jae-Young, et al.
Publicado: (2016)

GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis
por: Li, Qian, et al.
Publicado: (2020)

Evaluating somatic tumor mutation detection without matched normal samples
por: Teer, Jamie K., et al.
Publicado: (2017)

Cell-surface marker discovery for lung cancer
por: Cohen, Allison S., et al.
Publicado: (2017)

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
por: Machida, Kazuya, et al.
Publicado: (2010)

A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma
por: Stewart, Paul A., et al.
Publicado: (2015)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

Overview of approaches to estimate real-world disease progression in lung cancer
por: Amorrortu, Rossybelle, et al.
Publicado: (2023)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
por: Creelan, Ben C, et al.
Publicado: (2017)

Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer
por: Tunali, Ilke, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
por: Brazelle, William, et al.
Publicado: (2010)

Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures
por: Berglund, Anders E., et al.
Publicado: (2017)

The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts
por: Sosa-García, Bernadette, et al.
Publicado: (2015)

RAS MAPK inhibitors deregulation in leukemia
por: Pasmant, Eric, et al.
Publicado: (2015)

Trim28 Contributes to EMT via Regulation of E-Cadherin and N-Cadherin in Lung Cancer Cell Lines
por: Chen, Lu, et al.
Publicado: (2014)

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Yoshida, Takeshi, et al.
Publicado: (2016)

Iterative rank-order normalization of gene expression microarray data
por: Welsh, Eric A, et al.
Publicado: (2013)

Escape Excel: A tool for preventing gene symbol and accession conversion errors
por: Welsh, Eric A., et al.
Publicado: (2017)

Clinical significance of EPHX2 deregulation in prostate cancer
por: Liu, Ming-Sheng, et al.
Publicado: (2020)

Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors
por: Engel, B E, et al.
Publicado: (2013)

NETO2 Is Deregulated in Breast, Prostate, and Colorectal Cancer and Participates in Cellular Signaling
por: Fedorova, Maria S., et al.
Publicado: (2020)

A Case Control Study of the Seroprevalence of Helicobacter pylori Proteins and Their Association with Pancreatic Cancer Risk
por: Permuth, Jennifer B., et al.
Publicado: (2021)

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model
por: Sarcar, Bhaswati, et al.
Publicado: (2019)

FAS system deregulation in T-cell lymphoblastic lymphoma
por: Villa-Morales, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3d8tfukfaaalu6diipaog90pei